{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T14:55:57Z","timestamp":1774536957365,"version":"3.50.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No.82141119 and No.82070202"],"award-info":[{"award-number":["No.82141119 and No.82070202"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>To evaluate targeted therapy for Langerhans cell histiocytosis (LCH) with maxillofacial manifestations, we conducted a retrospective study of 20 children admitted from January 2016 to June 2021.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      The maxillofacial LCH exhibited diverse clinical features and laboratory indices. Seventeen patients were refractory to standard treatments, and three patients directly underwent targeted therapy. Sixteen patients with\n                      <jats:italic>BRAF<\/jats:italic>\n                      <jats:sup>\n                        <jats:italic>V600E<\/jats:italic>\n                      <\/jats:sup>\n                      mutation were treated with dabrafenib, and four patients with\n                      <jats:italic>MAP2K1<\/jats:italic>\n                      mutation were treated with trametinib.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The cohort included nine males and eleven females, with a median 0.92 years at diagnosis and 1.70 years at initiation of targeted therapy. Three patients had single-system LCH and 17 patients had multi-system LCH. Lesions affected the mandibular bone in 17 patients, the temporal bone in 12 patients, and the maxilla in 10 patients. Ki-67 expression before targeted therapy correlates with maxillary involvement (coefficient 0.61;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.05). The\n                      <jats:italic>cfBRAF<\/jats:italic>\n                      <jats:sup>\n                        <jats:italic>V600E<\/jats:italic>\n                      <\/jats:sup>\n                      level after first month of targeted therapy was significantly lower than before targeted therapy (\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.001). After a median 18 months of targeted therapy and 22 months of follow-up, 17 patients achieved complete remission, and 3 patients achieved partial remission. The objective response rate was 65%, and the disease control rate was 100%. Five patients experienced progression or reactivation, and ten patients had skin rashes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Overall, targeted therapy demonstrated good efficacy with mild tolerable adverse events.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-026-04301-w","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T14:02:14Z","timestamp":1774533734000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeted therapy for Langerhans cell histiocytosis with maxillofacial involvement in 20 children"],"prefix":"10.1186","volume":"21","author":[{"given":"Yang","family":"Jiang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhigang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9946-8567","authenticated-orcid":false,"given":"Tianyou","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guoxia","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,26]]},"reference":[{"issue":"22","key":"4301_CR1","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.1182\/blood-2016-01-690636","volume":"127","author":"JF Emile","year":"2016","unstructured":"Emile JF, Abla O, Fraitag S, Horne A, Haroche J, Donadieu J, et al. Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. Blood. 2016;127(22):2672\u201381.","journal-title":"Blood"},{"key":"4301_CR2","doi-asserted-by":"crossref","unstructured":"Allen CE, Merad M, McClain KL. Langerhans-cell histiocytosis. Longo DL, editor. N Engl J Med. 2018;379(9):856\u201368.","DOI":"10.1056\/NEJMra1607548"},{"issue":"5","key":"4301_CR3","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.arcped.2019.05.015","volume":"26","author":"S H\u00e9ritier","year":"2019","unstructured":"H\u00e9ritier S, Emile JF, H\u00e9lias-Rodzewicz Z, Donadieu J. Progress towards molecular-based management of childhood Langerhans cell histiocytosis. Arch P\u00e9diatrie. 2019;26(5):301\u20137.","journal-title":"Arch P\u00e9diatrie"},{"issue":"3","key":"4301_CR4","doi-asserted-by":"publisher","first-page":"156","DOI":"10.54589\/aol.36\/3\/156","volume":"36","author":"H Pavan","year":"2023","unstructured":"Pavan H, Fern\u00e1ndez V, De Preliasco V, Ienco M, Benchuya C. Langerhans cell histiocytosis oral lesions in pediatric patients. Acta Odontol\u00f3gica Latinoam. 2023;36(3):156\u201362.","journal-title":"Acta Odontol\u00f3gica Latinoam"},{"issue":"6","key":"4301_CR5","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1111\/bjh.14140","volume":"174","author":"C Rigaud","year":"2016","unstructured":"Rigaud C, Barkaoui MA, Thomas C, Bertrand Y, Lambilliotte A, Miron J, et al. Langerhans cell histiocytosis: therapeutic strategy and outcome in a 30-year nationwide cohort of 1478 patients under 18 years of age. Br J Haematol. 2016;174(6):887\u201398.","journal-title":"Br J Haematol"},{"issue":"3","key":"4301_CR6","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.joms.2021.10.014","volume":"80","author":"J Xu","year":"2022","unstructured":"Xu J, Gilbert JR, Sutton KS, Goudy SL, Abramowicz S. Head and Neck Langerhans Cell Histiocytosis in Children. J Oral Maxillofac Surg. 2022;80(3):545\u201352.","journal-title":"J Oral Maxillofac Surg"},{"issue":"6","key":"4301_CR7","doi-asserted-by":"publisher","first-page":"3341","DOI":"10.1007\/s00784-021-03873-0","volume":"25","author":"JC Difloe-Geisert","year":"2021","unstructured":"Difloe-Geisert JC, Bernauer SA, Schneeberger N, Bornstein MM, Walter C. Periodontal manifestations of Langerhans cell histiocytosis: a systematic review. Clin Oral Investig. 2021;25(6):3341\u20139.","journal-title":"Clin Oral Investig"},{"issue":"9","key":"4301_CR8","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1136\/archdischild-2016-312185","volume":"102","author":"TW Chow","year":"2017","unstructured":"Chow TW, Leung WK, Cheng FWT, Kumta SM, Chu WCW, Lee V, et al. Late outcomes in children with Langerhans cell histiocytosis. Arch Dis Child. 2017;102(9):830\u20135.","journal-title":"Arch Dis Child"},{"issue":"6","key":"4301_CR9","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/j.jpeds.2010.03.001","volume":"156","author":"N Grois","year":"2010","unstructured":"Grois N, Fahrner B, Arceci RJ, Henter JI, McClain K, Lassmann H, et al. Central Nervous System Disease in Langerhans Cell Histiocytosis. J Pediatr. 2010;156(6):873\u2013e8811.","journal-title":"J Pediatr"},{"key":"4301_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2017\/1691403","volume":"2017","author":"MA Altay","year":"2017","unstructured":"Altay MA, Sindel A, \u00d6zalp \u00d6, Kocabalkan B, \u00d6zbudak \u0130H, Erdem R, et al. Langerhans Cell Histiocytosis: A Diagnostic Challenge in the Oral Cavity. Case Rep Pathol. 2017;2017:1\u20136.","journal-title":"Case Rep Pathol"},{"issue":"1","key":"4301_CR11","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1182\/hematology.2025000708","volume":"2025","author":"OS Eckstein","year":"2025","unstructured":"Eckstein OS, Gulati N. Advances in the diagnosis and management of pediatric Langerhans cell histiocytosis and Rosai-Dorfman disease: therapies, biomarkers, and response assessment. Hematology. 2025;2025(1):215\u201328.","journal-title":"Hematology"},{"issue":"17","key":"4301_CR12","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.1182\/blood.2021014343","volume":"139","author":"G Goyal","year":"2022","unstructured":"Goyal G, Tazi A, Go RS, Rech KL, Picarsic JL, Vassallo R, et al. International expert consensus recommendations for the diagnosis and treatment of Langerhans cell histiocytosis in adults. Blood. 2022;139(17):2601\u201321.","journal-title":"Blood"},{"issue":"7","key":"4301_CR13","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S1368-8375(03)00080-0","volume":"39","author":"A Eckardt","year":"2003","unstructured":"Eckardt A, Schultze A. Maxillofacial manifestations of Langerhans cell histiocytosis: a clinical and therapeutic analysis of 10 patients. Oral Oncol. 2003;39(7):687\u201394.","journal-title":"Oral Oncol"},{"issue":"4","key":"4301_CR14","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s10006-021-00949-9","volume":"25","author":"A Chugh","year":"2021","unstructured":"Chugh A, Kaur A, Kumar Patnana A, Kumar P, Chugh VK. Unisystem Langerhans cell histiocytosis in maxillofacial region in pediatrics: comprehensive and systematic review. Oral Maxillofac Surg. 2021;25(4):429\u201344.","journal-title":"Oral Maxillofac Surg"},{"issue":"6","key":"4301_CR15","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1111\/jop.13207","volume":"50","author":"ISP Faustino","year":"2021","unstructured":"Faustino ISP, Fernandes PM, Pontes HAR, Mosqueda-Taylor A, Santos\u2010Silva AR, Vargas PA, et al. Langerhans cell histiocytosis in the oral and maxillofacial region: An update. J Oral Pathol Med. 2021;50(6):565\u201371.","journal-title":"J Oral Pathol Med"},{"issue":"2","key":"4301_CR16","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1002\/pbc.24367","volume":"60","author":"R Haupt","year":"2013","unstructured":"Haupt R, Minkov M, Astigarraga I, Sch\u00e4fer E, Nanduri V, Jubran R, et al. Langerhans cell histiocytosis (LCH): Guidelines for diagnosis, clinical work-up, and treatment for patients till the age of 18 years. Pediatr Blood Cancer. 2013;60(2):175\u201384.","journal-title":"Pediatr Blood Cancer"},{"issue":"25","key":"4301_CR17","doi-asserted-by":"publisher","first-page":"3023","DOI":"10.1200\/JCO.2015.65.9508","volume":"34","author":"S H\u00e9ritier","year":"2016","unstructured":"H\u00e9ritier S, Emile JF, Barkaoui MA, Thomas C, Fraitag S, Boudjemaa S, et al. BRAF Mutation Correlates With High-Risk Langerhans Cell Histiocytosis and Increased Resistance to First-Line Therapy. J Clin Oncol. 2016;34(25):3023\u201330.","journal-title":"J Clin Oncol"},{"issue":"11","key":"4301_CR18","doi-asserted-by":"publisher","first-page":"2892","DOI":"10.1111\/apa.16014","volume":"110","author":"C Rodriguez-Galindo","year":"2021","unstructured":"Rodriguez-Galindo C. Clinical features and treatment of Langerhans cell histiocytosis. Acta Paediatr. 2021;110(11):2892\u2013902.","journal-title":"Acta Paediatr"},{"issue":"5","key":"4301_CR19","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1111\/cup.13918","volume":"48","author":"A Bonometti","year":"2021","unstructured":"Bonometti A, Ferrario G, Parafioriti A, Giardino D, Simonetti F, Ginori A, et al. MAP2K1 - driven mixed Langerhans cell histiocytosis, Rosai\u2010Dorfman\u2010Destombes disease and Erdheim\u2010Chester disease, clonally related to acute myeloid leukemia. J Cutan Pathol. 2021;48(5):637\u201343.","journal-title":"J Cutan Pathol"},{"issue":"S1","key":"4301_CR20","doi-asserted-by":"publisher","first-page":"S65","DOI":"10.5045\/br.2021.2021013","volume":"56","author":"JK Suh","year":"2021","unstructured":"Suh JK, Kang S, Kim H, Im HJ, Koh KN. Recent advances in the understanding of the molecular pathogenesis and targeted therapy options in Langerhans cell histiocytosis. BLOOD Res. 2021;56(S1):S65\u20139.","journal-title":"BLOOD Res"},{"issue":"1","key":"4301_CR21","doi-asserted-by":"publisher","first-page":"261","DOI":"10.4143\/crt.2020.769","volume":"53","author":"Y Yang","year":"2021","unstructured":"Yang Y, Wang D, Cui L, Ma HH, Zhang L, Lian HY, et al. Effectiveness and Safety of Dabrafenib in the Treatment of 20 Chinese Children with BRAFV600E-Mutated Langerhans Cell Histiocytosis. Cancer Res Treat. 2021;53(1):261\u20139.","journal-title":"Cancer Res Treat"},{"issue":"12","key":"4301_CR22","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1002\/onco.13541","volume":"25","author":"AZ Hazim","year":"2020","unstructured":"Hazim AZ, Ruan GJ, Ravindran A, Abeykoon JP, Scheckel C, Vassallo R, et al. Efficacy of BRAF-Inhibitor Therapy in BRAF V600E -Mutated Adult Langerhans Cell Histiocytosis. Oncologist. 2020;25(12):1001\u20134.","journal-title":"Oncologist"},{"issue":"3","key":"4301_CR23","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1200\/JCO.22.01000","volume":"41","author":"E Bouffet","year":"2023","unstructured":"Bouffet E, Geoerger B, Moertel C, Whitlock JA, Aerts I, Hargrave D, Osterloh L, Tan E, Choi J, Russo M, Fox E. Efficacy and Safety of Trametinib Monotherapy or in Combination With Dabrafenib in Pediatric BRAF V600-Mutant Low-Grade Glioma. J Clin Oncol. 2023;41(3):664\u201374.","journal-title":"J Clin Oncol"},{"key":"4301_CR24","unstructured":"NCCN Clinical Practice Guidelines in Oncology. Histiocytic Neoplasms, Version 2.2025. 1502 https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=&id."},{"issue":"6","key":"4301_CR25","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.3892\/etm.2015.2396","volume":"9","author":"L Bi","year":"2015","unstructured":"Bi L, Sun B, Lu Z, Shi Z, Wang D, Zhu Z. Langerhans cell histiocytosis with multisystem involvement in an infant: A case report. Exp Ther Med. 2015;9(6):2137\u201340.","journal-title":"Exp Ther Med"},{"key":"4301_CR26","unstructured":"Thacker NH, Abla O. Pediatric Langerhans Cell Histiocytosis: State of the Science and Future Directions. 2019;17(2):122\u201331. https:\/\/pubmed.ncbi.nlm.nih.gov\/30845115\/"},{"key":"4301_CR27","doi-asserted-by":"publisher","first-page":"175883591987801","DOI":"10.1177\/1758835919878013","volume":"11","author":"N Neckel","year":"2019","unstructured":"Neckel N, Lissat A, Von Stackelberg A, Thieme N, Doueiri MS, Spors B, et al. Primary oral manifestation of Langerhans cell histiocytosis refractory to conventional therapy but susceptible to BRAF-specific treatment: a case report and review of the literature. Ther Adv Med Oncol. 2019;11:1758835919878013.","journal-title":"Ther Adv Med Oncol"},{"issue":"5","key":"4301_CR28","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1111\/bjh.13955","volume":"173","author":"M Aric\u00f2","year":"2016","unstructured":"Aric\u00f2 M. Langerhans cell histiocytosis in children: from the bench to bedside for an updated therapy. Br J Haematol. 2016;173(5):663\u201370.","journal-title":"Br J Haematol"},{"issue":"1","key":"4301_CR29","doi-asserted-by":"publisher","first-page":"6","DOI":"10.5114\/pdia.2017.67095","volume":"35","author":"M Jezierska","year":"2018","unstructured":"Jezierska M, Stefanowicz J, Romanowicz G, Kosiak W, Lange M. Langerhans cell histiocytosis in children \u2013 a disease with many faces. Recent advances in pathogenesis, diagnostic examinations and treatment. Adv Dermatol Allergol. 2018;35(1):6\u201317.","journal-title":"Adv Dermatol Allergol"},{"issue":"18","key":"4301_CR30","doi-asserted-by":"publisher","first-page":"5246","DOI":"10.1182\/bloodadvances.2022009067","volume":"7","author":"D Evseev","year":"2023","unstructured":"Evseev D, Osipova D, Kalinina I, Raykina E, Ignatova A, Lyudovskikh E, et al. Vemurafenib combined with cladribine and cytarabine results in durable remission of pediatric BRAF V600E\u2013positive LCH. Blood Adv. 2023;7(18):5246\u201357.","journal-title":"Blood Adv"},{"issue":"15","key":"4301_CR31","doi-asserted-by":"publisher","first-page":"3806","DOI":"10.1182\/bloodadvances.2022008414","volume":"7","author":"JA Whitlock","year":"2023","unstructured":"Whitlock JA, Geoerger B, Dunkel IJ, Roughton M, Choi J, Osterloh L, et al. Dabrafenib, alone or in combination with trametinib, in BRAF V600\u2013mutated pediatric Langerhans cell histiocytosis. Blood Adv. 2023;7(15):3806\u201315.","journal-title":"Blood Adv"},{"issue":"7","key":"4301_CR32","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1158\/1535-7163.MCT-20-1075","volume":"20","author":"CJ Wang","year":"2021","unstructured":"Wang CJ, Cui L, Ma HH, Wang D, Zhang L, Lian HY, et al. BRAF V600E Mutation in Cell-Free DNA, Rather than in Lesion Tissues, at Diagnosis Is An Independent Prognostic Factor in Children with Langerhans Cell Histiocytosis. Mol Cancer Ther. 2021;20(7):1316\u201323.","journal-title":"Mol Cancer Ther"},{"issue":"9","key":"4301_CR33","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1007\/s00432-021-03810-4","volume":"148","author":"Y Yang","year":"2022","unstructured":"Yang Y, Wang C, Wang D, Cui L, Li N, Lian H, et al. Clinical study of MAP2K1-mutated Langerhans cell histiocytosis in children. J Cancer Res Clin Oncol. 2022;148(9):2517\u201327.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"4","key":"4301_CR34","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s12105-017-0867-1","volume":"12","author":"NR Bedran","year":"2018","unstructured":"Bedran NR, Carlos R, De Andrade BAB, Bueno APS, Roma\u00f1ach MJ, Milito CB. Clinicopathological and Immunohistochemical Study of Head and Neck Langerhans Cell Histiocytosis from Latin America. Head Neck Pathol. 2018;12(4):431\u20139.","journal-title":"Head Neck Pathol"},{"issue":"6","key":"4301_CR35","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.ijporl.2010.03.017","volume":"74","author":"R Nicollas","year":"2010","unstructured":"Nicollas R, Rome A, Bela\u00efch H, Roman S, Volk M, Gentet JC, et al. Head and neck manifestation and prognosis of Langerhans\u2019 cell histiocytosis in children. Int J Pediatr Otorhinolaryngol. 2010;74(6):669\u201373.","journal-title":"Int J Pediatr Otorhinolaryngol"},{"key":"4301_CR36","unstructured":"Histiocyte society clinical practice guidelines for histiocytosis. Httpshistioorglangerhans-Cell-Histiocytosis\u2013Adults. https:\/\/histio.org\/langerhans-cell-histiocytosis-in-adults\/."},{"key":"4301_CR37","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE). 210 AD https:\/\/www.cancer.gov\/research\/resources\/resource."},{"issue":"9","key":"4301_CR38","doi-asserted-by":"publisher","first-page":"104","DOI":"10.3390\/children7090104","volume":"7","author":"S Capodiferro","year":"2020","unstructured":"Capodiferro S, Tempesta A, Limongelli L, Ingravallo G, Maiorano E, Sfasciotti GL, et al. Primary Oro-Facial Manifestations of Langerhans Cell Histiocytosis in Pediatric Age: A Bi-Institutional Retrospective Study on 45 Cases. Children. 2020;7(9):104.","journal-title":"Children"},{"issue":"12","key":"4301_CR39","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1182\/blood-2015-03-635151","volume":"126","author":"J Donadieu","year":"2015","unstructured":"Donadieu J, Bernard F, Van Noesel M, Barkaoui M, Bardet O, Mura R, et al. Cladribine and cytarabine in refractory multisystem Langerhans cell histiocytosis: results of an international phase 2 study. Blood. 2015;126(12):1415\u201323.","journal-title":"Blood"},{"issue":"10295","key":"4301_CR40","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S0140-6736(21)00311-1","volume":"398","author":"JF Emile","year":"2021","unstructured":"Emile JF, Cohen-Aubart F, Collin M, Fraitag S, Idbaih A, Abdel-Wahab O, et al. Histiocytosis Lancet. 2021;398(10295):157\u201370.","journal-title":"Histiocytosis Lancet"},{"key":"4301_CR41","unstructured":"Nezafati S, Yazdani J, Shahi S, Mehryari M, Hajmohammadi Somarin E. Outcome of surgery as sole treatment of eosinophilic granuloma of jaws. J Dent. 2019;20(3)."},{"issue":"8","key":"4301_CR42","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1177\/1066896919855774","volume":"27","author":"X Liu","year":"2019","unstructured":"Liu X, Zhang Y, Zhou CX. High Prevalence of BRAF V600E Mutations in Langerhans Cell Histiocytosis of Head and Neck in Chinese Patients. Int J Surg Pathol. 2019;27(8):836\u201343.","journal-title":"Int J Surg Pathol"},{"issue":"31","key":"4301_CR43","doi-asserted-by":"publisher","first-page":"2857","DOI":"10.1200\/JCO.19.00456","volume":"37","author":"J Donadieu","year":"2019","unstructured":"Donadieu J, Larabi IA, Tardieu M, Visser J, Hutter C, Sieni E, et al. Vemurafenib for Refractory Multisystem Langerhans Cell Histiocytosis in Children: An International Observational Study. J Clin Oncol. 2019;37(31):2857\u201365.","journal-title":"J Clin Oncol"},{"issue":"4","key":"4301_CR44","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1084\/jem.20130977","volume":"211","author":"ML Berres","year":"2014","unstructured":"Berres ML, Lim KPH, Peters T, Price J, Takizawa H, Salmon H, et al. BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups. J Exp Med. 2014;211(4):669\u201383.","journal-title":"J Exp Med"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04301-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-026-04301-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04301-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T14:02:19Z","timestamp":1774533739000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13023-026-04301-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,26]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4301"],"URL":"https:\/\/doi.org\/10.1186\/s13023-026-04301-w","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,26]]},"assertion":[{"value":"3 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Approval of the research protocol by an Institutional Review Board: Medical Research Committee of Beijing Children\u2019s Hospital, Capital Medical University. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Consent for publication was obtained for every person\u2019s data included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no conflicts of interest.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"109"}}